Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâs products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Employees

1,069

Sector

Biotechnology & Medical Research

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-13	35.28 $	-0.95%	44,477
25-06-12	35.62 $	-1.58%	1,683,419
25-06-11	36.19 $	-1.76%	1,577,314
25-06-10	36.84 $	+0.22%	1,596,394
25-06-09	36.76 $	+4.17%	2,032,616

Delayed Quote Nasdaq, June 12, 2025 at 04:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

35.62USD

Average target price

57.66USD

Spread / Average Target

+61.86%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:12:21 2025-06-13 EDT			5-day change	1st Jan Change
35.52 ^USD	-0.28%		-0.03%	+0.92%

06-12	Ionis Pharmaceuticals, Inc. Announces Executive Changes	CI
06-12	Ionis Pharmaceuticals Announces Dr Richard Geary, Chief Development Officer, To Retire	RE

Capitalization	5.67B 4.9B 4.61B 4.17B 7.72B 485B 8.69B 53.58B 20.92B 223B 21.27B 20.82B 815B	P/E ratio 2025 *	-11.6x	P/E ratio 2026 *	-11.3x
Enterprise value	4.93B 4.26B 4.01B 3.63B 6.72B 423B 7.57B 46.64B 18.21B 194B 18.51B 18.12B 709B	EV / Sales 2025 *	6.6x	EV / Sales 2026 *	6x
Free-Float	99.23%	Yield 2025 *	-	Yield 2026 *	-

Ionis Pharmaceuticals, Inc. Announces Executive Changes	06-12	CI
Ionis Pharmaceuticals Announces Dr Richard Geary, Chief Development Officer, To Retire	06-12	RE
Ionis Pharmaceuticals Doses First Participant In Phase 3 Study For Angelman Syndrome Treatment	06-11	CI
Ionis Pharmaceuticals, Inc. - Shareholder/Analyst Call	06-05
Ionis Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 08:00 AM	05-21
Ionis Pharmaceuticals Says Olezarsen Trial Meets Primary Endpoint, All Key Secondary Endpoints	05-19	MT
Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Essence Study of Olezarsen in People with Moderate Hypertriglycerides	05-19	CI
Ionis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09:20 AM	05-14
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says	05-01	MT
Ionis Pharmaceuticals, Inc., Q1 2025 Earnings Call, Apr 30, 2025	04-30
Ionis Pharmaceuticals Q1 Net Loss Narrows as Revenue Increases; 2025 Revenue Guidance Raised	04-30	MT
Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 EPS Loss $0.93, vs. FactSet Est of $1.10 Loss	04-30	MT
Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 Revenue $132M, vs. FactSet Est of $131.4M	04-30	MT

HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target	04-07	MT
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target	03-31	MT
Analyst recommendations: Roku, Applovin, Carvana, Doordash, Etsy...	02-20
BMO Capital Downgrades Ionis Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $60 From $67	24-08-02	MT
Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....	24-08-02

Ionis Pharmaceuticals, Inc. Stock

Equities

IONS

US4622221004

Biotechnology & Medical Research

Valuation: Ionis Pharmaceuticals, Inc.

Chart: Ionis Pharmaceuticals, Inc.

Latest news: Ionis Pharmaceuticals, Inc.

Last Transcript: Ionis Pharmaceuticals, Inc.

Analysts' recommendations: Ionis Pharmaceuticals, Inc.

Press Releases: Ionis Pharmaceuticals, Inc.

News in other languages: Ionis Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ionis Pharmaceuticals, Inc.

ETFs: Ionis Pharmaceuticals, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Ionis announces Dr. Richard Geary, chief development officer, to retire, Dr. Holly Kordasiewicz to assume role in January 2026	08:34am	AQ
Ionis Pharmaceuticals, Inc. - First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome	06-12	AQ
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026	06-12	BU
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome	06-11	BU
Ionis Pharmaceuticals : 2026 06 05 Ionis ASM Presentation	06-05	PU

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Alphabet, Amazon, Lululemon, Intel, Qualcomm....	24-08-02
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk	24-06-24
Recomendaciones de los analistas UK/EE.UU: Adobe, Bank of America, Boeing, Nvidia, Wise...	24-06-14
GSK : une procédure accélérée dans l'hépatite aux USA	24-02-12
Nike et Tencent se ratent pour Noël	23-12-22

1 day	-1.58%
1 week	+1.08%
Current month	+6.30%
1 month	+6.23%
3 months	+6.61%
6 months	-3.76%
Current year	+1.89%

1 week	35.3	37.6
1 month	32	37.6
Current year	23.95	37.6
1 year	23.95	52.34
3 years	23.95	54.44
5 years	23.95	64.37
10 years	19.59	86.58

Manager	Title	Age	Since
Brett Monia CEO	Chief Executive Officer	63	2019-12-31
D. Walke IRC	Investor Relations Contact	59	2012-06-30
Elizabeth Hougen DFI	Director of Finance/CFO	63	2000-04-30

Director	Title	Age	Since
B. Parshall BRD	Director/Board Member	70	2000-08-31
Joseph Wender BRD	Director/Board Member	80	1993-12-31
Joseph Klein BRD	Director/Board Member	63	2005-12-12

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IONIS PHARMACEUTICALS, INC.	-1.58%	+1.08%	-14.17%	+2.47%	5.67B
LONZA GROUP AG	-1.58%	+0.28%	+19.52%	+10.49%	50.66B
IQVIA HOLDINGS INC.	+0.19%	+7.98%	-26.82%	-23.26%	27.53B
CELLTRION, INC.	+1.05%	+4.51%	-4.60%	+16.70%	26.72B
EUROFINS SCIENTIFIC SE	-0.20%	+3.32%	+13.39%	-24.44%	12.56B
TEMPUS AI, INC.	+0.64%	+21.43%	-	-	12.33B
ICON PUBLIC LIMITED COMPANY	+1.06%	+9.10%	-54.00%	-32.91%	11.69B
MODERNA, INC.	-1.44%	+4.71%	-81.49%	-78.48%	10.58B
ASCENDIS PHARMA A/S	-0.47%	-3.73%	+30.20%	+106.47%	10.32B
QIAGEN N.V.	+1.43%	+4.02%	+4.17%	-0.42%	10.26B
Average	-0.97%	+5.91%	-12.64%	-2.60%	17.83B
Weighted average by Cap.	-0.93%	+5.85%	-5.56%	-0.46%

	2025 *	2026 *
Net sales	748M 646M 608M 550M 1.02B 64.03B 1.15B 7.07B 2.76B 29.42B 2.81B 2.75B 107B	867M 749M 705M 638M 1.18B 74.23B 1.33B 8.19B 3.2B 34.1B 3.25B 3.18B 125B
Net income	-481M -416M -392M -354M -656M -41.23B -738M -4.55B -1.78B -18.94B -1.81B -1.77B -69.19B	-501M -433M -407M -369M -682M -42.89B -768M -4.73B -1.85B -19.7B -1.88B -1.84B -71.98B
Net Debt	-734M -635M -597M -541M -1B -62.89B -1.13B -6.94B -2.71B -28.89B -2.76B -2.7B -106B	-466M -402M -379M -343M -634M -39.87B -714M -4.4B -1.72B -18.32B -1.75B -1.71B -66.92B